You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

Accent Therapeutics presents ATX-295 data at AACR Annual Meeting 2026

10x Genomics introduces new in situ spatial biology platform

Whitehawk Therapeutics presents ADC preclinical data at AACR 2026

Kura Oncology reports early activity for darlifarnib–cabozantinib combination in cabozantinib‑pretreated ccRCC

Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic

Bold Therapeutics reports protection against chemotherapy-induced peripheral neuropathy with BOLD-100 anticancer agent

Philips secures FDA clearance for Spectral CT Verida system

Circio partners with Acuitas to evaluate in vivo CAR-T cell therapy technology

Poolbeg Pharma secures MHRA approval for POLB 001 trial as US research highlights multi-billion dollar potential

Asgard Therapeutics appoints chief medical officer

Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting

Senhwa Biosciences secures up to TWD500m funding for AI-driven drug development

CrossBridge Bio to be acquired by Eli Lilly

IDEAYA Biosciences and Servier report positive results from Phase 2/3 trial of darovasertib/crizotinib combination

Kazia Therapeutics in-licenses SETDB1 inhibitor drug development platform

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026